JP2006514950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514950A5 JP2006514950A5 JP2004560831A JP2004560831A JP2006514950A5 JP 2006514950 A5 JP2006514950 A5 JP 2006514950A5 JP 2004560831 A JP2004560831 A JP 2004560831A JP 2004560831 A JP2004560831 A JP 2004560831A JP 2006514950 A5 JP2006514950 A5 JP 2006514950A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- optionally substituted
- aryl
- ring
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 17
- 229920006395 saturated elastomer Polymers 0.000 claims 16
- 229910052757 nitrogen Chemical group 0.000 claims 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 239000001301 oxygen Substances 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 229910052698 phosphorus Inorganic materials 0.000 claims 9
- 239000011574 phosphorus Chemical group 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 239000011593 sulfur Chemical group 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- -1 methylenedioxy, ethylenedioxy Chemical group 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 2
- 241000607479 Yersinia pestis Species 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 206010035148 Plague Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000006824 bubonic plague Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000004452 carbocyclyl group Chemical group 0.000 claims 1
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000021145 human papilloma virus infection Diseases 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003589 nefrotoxic effect Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 231100000381 nephrotoxic Toxicity 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43362602P | 2002-12-13 | 2002-12-13 | |
| PCT/US2003/039619 WO2004055010A2 (en) | 2002-12-13 | 2003-12-12 | Cyclopropyl compounds as ccr5 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514950A JP2006514950A (ja) | 2006-05-18 |
| JP2006514950A5 true JP2006514950A5 (enExample) | 2007-01-25 |
Family
ID=32595221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004560831A Pending JP2006514950A (ja) | 2002-12-13 | 2003-12-12 | Ｃｃｒ５拮抗薬としてのシクロプロピル化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7569579B2 (enExample) |
| EP (1) | EP1569934B1 (enExample) |
| JP (1) | JP2006514950A (enExample) |
| AT (1) | ATE384724T1 (enExample) |
| AU (1) | AU2003296993A1 (enExample) |
| DE (1) | DE60318891T2 (enExample) |
| ES (1) | ES2298627T3 (enExample) |
| WO (1) | WO2004055010A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005007614A1 (en) * | 2003-07-03 | 2005-01-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services 6011 | Monoamine oxidase inhibitors |
| CA2549660A1 (en) * | 2003-12-15 | 2005-06-30 | Japan Tobacco Inc. | Cyclopropane compounds and pharmaceutical use thereof |
| ES2442926T3 (es) | 2007-08-22 | 2014-02-14 | Astrazeneca Ab | Derivados de ciclopropilamida `978 |
| CN104530048B (zh) | 2008-08-11 | 2016-09-14 | 葛兰素史密丝克莱恩有限责任公司 | 腺嘌呤衍生物 |
| JP2011530562A (ja) | 2008-08-11 | 2011-12-22 | グラクソスミスクライン エルエルシー | アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体 |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| US8859555B2 (en) | 2009-09-25 | 2014-10-14 | Oryzon Genomics S.A. | Lysine Specific Demethylase-1 inhibitors and their use |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| JP2013519644A (ja) | 2010-02-10 | 2013-05-30 | グラクソスミスクライン エルエルシー | プリン誘導体およびそれらの薬学的使用 |
| CA2786973C (en) | 2010-02-10 | 2018-04-10 | Robert Hermann Gibbon | 6-amino-2-{[(1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate |
| NZ602110A (en) | 2010-02-18 | 2014-09-26 | Astrazeneca Ab | Processes for making cyclopropyl amide derivatives and intermediates associated therewith |
| WO2011106105A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
| RU2599248C2 (ru) | 2010-04-19 | 2016-10-10 | Оризон Дженомикс С.А. | Лизинспецифические ингибиторы деметилазы-1 и их применение |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| ME03085B (me) | 2010-07-29 | 2019-01-20 | Oryzon Genomics Sa | Demetilaza inhibitori lsd1 zasnovani na arilciklopropilaminu i njihova medicinska primjena |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| EP3981395A1 (en) | 2011-02-08 | 2022-04-13 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| BR112014009306B1 (pt) | 2011-10-20 | 2021-07-20 | Oryzon Genomics S.A. | Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1 |
| BR112014009238B1 (pt) | 2011-10-20 | 2022-08-09 | Oryzon Genomics S.A. | Compostos de (hetero)aril ciclopropilamina, seus usos e composições farmacêuticas |
| JO3387B1 (ar) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
| CN106029668B (zh) | 2014-02-20 | 2018-02-23 | 葛兰素史克知识产权第二有限公司 | 吡咯并[3,2]嘧啶衍生物作为人类干扰素诱导剂 |
| MX2017006302A (es) | 2014-11-13 | 2018-02-16 | Glaxosmithkline Biologicals Sa | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. |
| CR20180286A (es) | 2015-12-03 | 2018-07-16 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos de purina cíclicos como moduladores de sting |
| BR112018070602A2 (pt) | 2016-04-07 | 2019-02-05 | Glaxosmithkline Ip Dev Ltd | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio |
| SI3440076T1 (sl) | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
| TW201927771A (zh) | 2017-10-05 | 2019-07-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 可作為蛋白質調節劑之雜環醯胺及其使用方法 |
| JP7291130B2 (ja) | 2017-10-05 | 2023-06-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質 |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| JP2022533194A (ja) | 2019-05-16 | 2022-07-21 | スティングセラ インコーポレイテッド | ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法 |
| EP3969438A1 (en) | 2019-05-16 | 2022-03-23 | Stingthera, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| AU2020409429A1 (en) | 2019-12-18 | 2022-06-16 | Ctxt Pty Ltd | Compounds |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331541B1 (en) * | 1998-12-18 | 2001-12-18 | Soo S. Ko | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| AU770042B2 (en) * | 1998-12-18 | 2004-02-12 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US7217714B1 (en) | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
| PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| ATE348099T1 (de) * | 2001-02-16 | 2007-01-15 | Aventis Pharma Inc | Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden |
-
2003
- 2003-12-12 ES ES03813416T patent/ES2298627T3/es not_active Expired - Lifetime
- 2003-12-12 AT AT03813416T patent/ATE384724T1/de not_active IP Right Cessation
- 2003-12-12 WO PCT/US2003/039619 patent/WO2004055010A2/en not_active Ceased
- 2003-12-12 AU AU2003296993A patent/AU2003296993A1/en not_active Abandoned
- 2003-12-12 JP JP2004560831A patent/JP2006514950A/ja active Pending
- 2003-12-12 DE DE60318891T patent/DE60318891T2/de not_active Expired - Lifetime
- 2003-12-12 EP EP03813416A patent/EP1569934B1/en not_active Expired - Lifetime
- 2003-12-12 US US10/538,196 patent/US7569579B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514950A5 (enExample) | ||
| JP2006511555A5 (enExample) | ||
| JP2006511552A5 (enExample) | ||
| JP2006512339A5 (enExample) | ||
| CN101969951B (zh) | 化合物在制备治疗关节炎的药物中的方法 | |
| AU2014277506B2 (en) | Bisulfate of Janus kinase (JAK) inhibitor and preparation method therefor | |
| RU2006144709A (ru) | Земещенные 2-хинолилоксазолы, пригодные в качестве ингибиторы фдэ4 | |
| WO2018057973A4 (en) | Compounds and methods for ido and tdo modulation, and indications therefor | |
| RU2013154117A (ru) | Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы | |
| RU2002131887A (ru) | Замещенные в орто-положении амиды антраниловой кислоты и их применение в качестве лекарственных средств | |
| RU2006105716A (ru) | Производные пиридазина и их применение в качестве терапевтических средств | |
| JP2008526761A5 (enExample) | ||
| RU2003103291A (ru) | Ингибиторы медьсодержащих аминооксидаз | |
| RU2015105262A (ru) | Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах | |
| JP2011506412A5 (enExample) | ||
| RU2006130684A (ru) | Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов | |
| JP2017510643A5 (enExample) | ||
| RU2016150326A (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| JP2002535401A5 (enExample) | ||
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| RU2011117927A (ru) | Карбаматное соединение или его соль | |
| RU99112569A (ru) | Бициклические арильные карбоксамиды и их терапевтическое применение | |
| WO2019173613A1 (en) | Substituted fused pyrrolo-diazepinones and uses thereof | |
| RU2010101307A (ru) | Замещенные (оксазолидинон-5ил-метил)-2-тиофен-карбоксамиды и их применение в области свертывания крови | |
| Majewski et al. | Design, syntheses, and anti-tuberculosis activities of conjugates of piperazino-1, 3-benzothiazin-4-ones (pBTZs) with 2, 7-dimethylimidazo [1, 2-a] pyridine-3-carboxylic acids and 7-phenylacetyl cephalosporins |